Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913983 | 0.85 | SMN1; SMN2 (0.49) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL919529 | 0.85 | ALOX5 (0.48) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL212724 | 0.82 | ALOX5 (0.64) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL16397645 | 0.82 | ALOX5 (0.64) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL914240 | 0.81 | CA12 (0.59) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL23532714 | 0.81 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL27648673 | 0.81 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL5770308 | 0.81 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6755749 | 0.79 | ALOX5 (0.43) | ALOX5NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7216396 | 0.78 | GRM5 (0.51) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247587-B1 | 5-OXO-2, 3,4,5-TETRAHYDRO-BENZO[B]OXEPINE-4-CARBOXYLIC ACID AMIDES AND 2,3-DIHYDRO-BENZO[B]OXEPINE-4-CARBOXYLIC ACID AMIDES FOR TREATMENT AND PREVENTION OF DIABETES TYP 1 AND 2 | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8383838-B2 | 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110009455-A1 | 5-Oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-Dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of Diabetes Typ 1 and 2 | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2247587-A1 | 5-OXO-2, 3,4,5-TETRAHYDRO-BENZO[B]OXEPINE-4-CARBOXYLIC ACID AMIDES AND 2,3-DIHYDRO-BENZO[B]OXEPINE-4-CARBOXYLIC ACID AMIDES FOR TREATMENT AND PREVENTION OF DIABETES TYP 1 AND 2 | Merck Patent GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009109270-A1 | 5-OXO-2, 3,4,5-TETRAHYDRO-BENZO[B]OXEPINE-4-CARBOXYLIC ACID AMIDES AND 2,3-DIHYDRO-BENZO[B]OXEPINE-4-CARBOXYLIC ACID AMIDES FOR TREATMENT AND PREVENTION OF DIABETES TYP 1 AND 2 | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009079011-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-1760054-A2 | Process for producing cyclic compound | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-7038042-B2 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20030040632-A1 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1266881-A1 | PROCESS FOR PRODUCING CYCLIC COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2002-12-18 | — | — | EP | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| EP-1140893-A1 | BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS | MERCK PATENT GmbH (DE) | 2001-10-10 | — | — | EP | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000039113-A1 | BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS | MERCK PATENT GMBH (DE) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998016527-A1 | BENZOXEPINE DERIVATIVES WHICH PROMOTE RELEASE OF GROWTH HORMONE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040632-A1 | Process for producing cyclic compound | CTH, DOHH, SLC39A11 | ALOX5 3076/4885SMN1; SMN2 3171/4885NPC1 2059/4885 |
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, ROCK2, ARHGDIB | ALOX5 4290/4885SMN1; SMN2 3133/4885NPC1 1508/4885 |
| US-20110009455-A1 | 5-Oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-Dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of Diabetes Typ 1 and 2 | GPR119, HK1, GCKR | ALOX5 383/4885SMN1; SMN2 4124/4885NPC1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.